Greenland Mines Ltd. Common Stock (NASDAQ:GRML) Stock Short Interest Report for September

Greenland Mines Ltd. Common Stock (NASDAQ:GRML) was the recipient of a large increase in short interest in September. As of September 30th, there was short interest totaling 935,276 shares, an increase of 83.9% from the September 15th total of 508,658 shares. Approximately 8.8% of the shares of the company are short sold. Based on an average daily volume of 41,326,353 shares, the days-to-cover ratio is currently 0.0 days.

Insider Activity at Greenland Mines Ltd. Common Stock

In related news, Director Riad Hussein El-Dada sold 3,500 shares of Greenland Mines Ltd. Common Stock stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $9.35, for a total value of $32,725.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jason David Sawyer bought 4,800 shares of the company’s stock in a transaction dated Wednesday, July 22nd. The stock was bought at an average price of $11.50 per share, for a total transaction of $55,200.00. Following the transaction, the director owned 4,800 shares of the company’s stock, valued at approximately $55,200. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 11.30% of the company’s stock.

Institutional Trading of Greenland Mines Ltd. Common Stock

An institutional investor recently bought a new stake in Greenland Mines Ltd. Common Stock stock. Citadel Advisors LLC bought a new position in shares of Greenland Mines Ltd. Common Stock (NASDAQ:GRML) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 5,165,648 shares of the company’s stock, valued at approximately $1,343,000. Citadel Advisors LLC owned approximately 162.60% of Greenland Mines Ltd. Common Stock as of its most recent filing with the SEC. Institutional investors and hedge funds own 20.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on GRML shares. Weiss Ratings cut shares of Greenland Mines Ltd. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 9th. Wall Street Zen upgraded shares of Greenland Mines Ltd. Common Stock to a “sell” rating in a research report on Saturday, August 29th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Greenland Mines Ltd. Common Stock Price Performance

Shares of GRML traded down $0.96 during mid-day trading on Friday, reaching $6.00. The stock had a trading volume of 1,471,691 shares, compared to its average volume of 26,697,508. Greenland Mines Ltd. Common Stock has a 52-week low of $2.82 and a 52-week high of $36.99. The business’s fifty day moving average is $7.35 and its 200 day moving average is $13.84. The firm has a market cap of $72.18 million, a price-to-earnings ratio of -0.52 and a beta of 6.26.

Greenland Mines Ltd. Common Stock (NASDAQ:GRML) last posted its earnings results on Monday, August 17th. The company reported ($0.03) earnings per share (EPS) for the quarter.

Greenland Mines Ltd. Common Stock announced that its Board of Directors has authorized a stock buyback program on Tuesday, October 6th that authorizes the company to buy back $20.00 million in outstanding shares. This buyback authorization authorizes the company to buy up to 20.4% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Greenland Mines Ltd. Common Stock Company Profile

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases.